{"organizations": [], "uuid": "a0f284c13986353127cb7bf0d3565db6d957f2ea", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180129.html", "section_title": "Archive News &amp; Video for Monday, 29 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sorrento-says-china-oncology-focus/brief-sorrento-says-china-oncology-focus-received-approval-in-china-to-begin-clinical-trials-for-zkab001-idUSASB0C2QM", "country": "US", "domain_rank": 408, "title": "BRIEF-Sorrento Says China Oncology Focus Received Approval In China To Begin Clinical Trials For ZKAB001", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.987, "site_type": "news", "published": "2018-01-29T21:31:00.000+02:00", "replies_count": 0, "uuid": "a0f284c13986353127cb7bf0d3565db6d957f2ea"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sorrento-says-china-oncology-focus/brief-sorrento-says-china-oncology-focus-received-approval-in-china-to-begin-clinical-trials-for-zkab001-idUSASB0C2QM", "ord_in_thread": 0, "title": "BRIEF-Sorrento Says China Oncology Focus Received Approval In China To Begin Clinical Trials For ZKAB001", "locations": [], "entities": {"persons": [{"name": "sorrento", "sentiment": "none"}], "locations": [{"name": "china", "sentiment": "none"}, {"name": "china", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "sorrento therapeutics inc", "sentiment": "negative"}, {"name": "china oncology focus", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 29 (Reuters) - Sorrento Therapeutics Inc:\n* CHINA ONCOLOGY FOCUS LIMITED RECEIVES APPROVAL BY CHINESE AUTHORITIES TO BEGIN CLINICAL TRIALS IN THREE SEPARATE CANCER INDICATIONS USING SORRENTO’S ANTI-PD-L1 MONOCLONAL ANTIBODY\n* SORRENTO THERAPEUTICS - ‍CLINICAL DATA FROM STUDIES COULD BE AVAILABLE BY END OF YEAR 2019​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-29T21:31:00.000+02:00", "crawled": "2018-01-30T19:04:11.014+02:00", "highlightTitle": ""}